Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.

Investor Intent

Eli Lilly says it holds the shares for investment and may buy more or sell some in the future. The company may also use hedging tools, noting it "may engage in hedging or other transactions... including swaps and other derivative instruments."

Lilly agreed to a 180‑day lock-up from July 23, 2026, which limits sales or transfers without the underwriters’ consent. The company plans to "engage in discussions with directors, officers, members of management" and other stakeholders, may hire advisors, and currently has no specific plans for changes at Scribe.

Investor's Background

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company regularly partners with biotech firms and invests in innovative therapeutic platforms to expand its pipeline. Lilly focuses on areas such as diabetes, obesity, neuroscience, oncology, and immunology and has a long track record of large-scale drug development.

Original SEC Filing: Scribe Therapeutics, Inc. [ SCTX ] - SCHEDULE 13D - Jul. 30, 2026